A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia

Stefano Molica, Francesca R. Mauro, Vincenzo Callea, Massimo Gentile, Diana Giannarelli, Manuela Lopez, Francesco Lauria, Bruno Rotoli, Marco Montanaro, Agostino Cortelezzi, Vincenzo Liso, Franco Mandelli, Robin Foa, [No Value] Leoni, [No Value] Montanari, [No Value] Giustolisi, [No Value] Stagno, [No Value] Molica, [No Value] D'Arco, [No Value] Chiurazzi & 28 others [No Value] Mariani, [No Value] Iannitto, [No Value] Mirto, [No Value] Felici, [No Value] Ascari, [No Value] Invernizzi, [No Value] Nobile, [No Value] Leone, [No Value] Laurenti, [No Value] Longinotti, [No Value] Dore, [No Value] Lazzarino, [No Value] Pagnucco, Favero Del Favero, [No Value] Liberati, [No Value] Gallamini, [No Value] Zanella, [No Value] Barcellini, [No Value] Maiolo, [No Value] Petrini, [No Value] Galimberti, [No Value] Marotta, [No Value] Niscola, [No Value] Torelli, [No Value] Morselli, [No Value] Andriani, [No Value] Zamboni, [No Value] Miraglia

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

To facilitate the development of a prognostic model for early B-cell chronic lymphocytic leukemia (CLL), the Gruppo Italiano Malattie EMatologiche Maligne dell'Adulto (GIMEMA) proposes its multi-institutional effort as a working model. In total, 1138 newly diagnosed Binet stage A patients managed over the last 10 years outside the setting of clinical trials according to a "wait and see" policy form the basis of the present study aimed at investigating prognostic variables affecting disease progression, a surrogate endpoint for overall survival. A 3-stage risk system, simply obtained by summing the variables that proved significant in the multivariate analysis (i.e. short lymphocyte doubling time, advanced Rai substage, high peripheral blood lymphocytosis), is proposed. Clear-cut differences in the 10 year progression-free survival (PFS) were observed among patients scoring 0 (low risk), 1 (intermediate risk), 2 - 3 (high risk): 67.8, 41.0 and 24.8%, respectively (P <0.0001). The results of the Medical Research Council (MRC) suggesting a better clinical outcome for females prompted us to verify such a gender-related difference within our prognostic categories. Because changes in PFS only reflected gender for patients scoring 0 (P = 0.04), the following prognostic subgroups are proposed: (1) females scoring 0; (2) males scoring 0; (3) patients scoring 1 - 3 whatever gender (10 year PFS: 76.2, 61.4 and 37.8%; P <0.00001). Our long-term database provides an adequate patient sample to generate a generalized risk stratification model based on clinical data. The indolent clinical outcome of women with early CLL is also supported by the higher frequency of the immunoglobulin heavy-chain variable (IgVH) mutational status and lower proportion of 17p and 11q deletions found in such a patient subset in the MRC CLL4 trial.

Original languageEnglish
Pages (from-to)553-560
Number of pages8
JournalLeukemia and Lymphoma
Volume46
Issue number4
DOIs
Publication statusPublished - Apr 2005

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Disease-Free Survival
Biomedical Research
Lymphocytosis
Immunoglobulin Heavy Chains
Disease Progression
Multivariate Analysis
Biomarkers
Clinical Trials
Databases
Lymphocytes
Survival

Keywords

  • Disease progression
  • Early CLL
  • Gender

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia. / Molica, Stefano; Mauro, Francesca R.; Callea, Vincenzo; Gentile, Massimo; Giannarelli, Diana; Lopez, Manuela; Lauria, Francesco; Rotoli, Bruno; Montanaro, Marco; Cortelezzi, Agostino; Liso, Vincenzo; Mandelli, Franco; Foa, Robin; Leoni, [No Value]; Montanari, [No Value]; Giustolisi, [No Value]; Stagno, [No Value]; Molica, [No Value]; D'Arco, [No Value]; Chiurazzi, [No Value]; Mariani, [No Value]; Iannitto, [No Value]; Mirto, [No Value]; Felici, [No Value]; Ascari, [No Value]; Invernizzi, [No Value]; Nobile, [No Value]; Leone, [No Value]; Laurenti, [No Value]; Longinotti, [No Value]; Dore, [No Value]; Lazzarino, [No Value]; Pagnucco, [No Value]; Del Favero, Favero; Liberati, [No Value]; Gallamini, [No Value]; Zanella, [No Value]; Barcellini, [No Value]; Maiolo, [No Value]; Petrini, [No Value]; Galimberti, [No Value]; Marotta, [No Value]; Niscola, [No Value]; Torelli, [No Value]; Morselli, [No Value]; Andriani, [No Value]; Zamboni, [No Value]; Miraglia, [No Value].

In: Leukemia and Lymphoma, Vol. 46, No. 4, 04.2005, p. 553-560.

Research output: Contribution to journalArticle

Molica, S, Mauro, FR, Callea, V, Gentile, M, Giannarelli, D, Lopez, M, Lauria, F, Rotoli, B, Montanaro, M, Cortelezzi, A, Liso, V, Mandelli, F, Foa, R, Leoni, NV, Montanari, NV, Giustolisi, NV, Stagno, NV, Molica, NV, D'Arco, NV, Chiurazzi, NV, Mariani, NV, Iannitto, NV, Mirto, NV, Felici, NV, Ascari, NV, Invernizzi, NV, Nobile, NV, Leone, NV, Laurenti, NV, Longinotti, NV, Dore, NV, Lazzarino, NV, Pagnucco, NV, Del Favero, F, Liberati, NV, Gallamini, NV, Zanella, NV, Barcellini, NV, Maiolo, NV, Petrini, NV, Galimberti, NV, Marotta, NV, Niscola, NV, Torelli, NV, Morselli, NV, Andriani, NV, Zamboni, NV & Miraglia, NV 2005, 'A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia', Leukemia and Lymphoma, vol. 46, no. 4, pp. 553-560. https://doi.org/10.1080/10428190400029965
Molica, Stefano ; Mauro, Francesca R. ; Callea, Vincenzo ; Gentile, Massimo ; Giannarelli, Diana ; Lopez, Manuela ; Lauria, Francesco ; Rotoli, Bruno ; Montanaro, Marco ; Cortelezzi, Agostino ; Liso, Vincenzo ; Mandelli, Franco ; Foa, Robin ; Leoni, [No Value] ; Montanari, [No Value] ; Giustolisi, [No Value] ; Stagno, [No Value] ; Molica, [No Value] ; D'Arco, [No Value] ; Chiurazzi, [No Value] ; Mariani, [No Value] ; Iannitto, [No Value] ; Mirto, [No Value] ; Felici, [No Value] ; Ascari, [No Value] ; Invernizzi, [No Value] ; Nobile, [No Value] ; Leone, [No Value] ; Laurenti, [No Value] ; Longinotti, [No Value] ; Dore, [No Value] ; Lazzarino, [No Value] ; Pagnucco, [No Value] ; Del Favero, Favero ; Liberati, [No Value] ; Gallamini, [No Value] ; Zanella, [No Value] ; Barcellini, [No Value] ; Maiolo, [No Value] ; Petrini, [No Value] ; Galimberti, [No Value] ; Marotta, [No Value] ; Niscola, [No Value] ; Torelli, [No Value] ; Morselli, [No Value] ; Andriani, [No Value] ; Zamboni, [No Value] ; Miraglia, [No Value]. / A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia. In: Leukemia and Lymphoma. 2005 ; Vol. 46, No. 4. pp. 553-560.
@article{3322265f207a4747919674aabbd9fe55,
title = "A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia",
abstract = "To facilitate the development of a prognostic model for early B-cell chronic lymphocytic leukemia (CLL), the Gruppo Italiano Malattie EMatologiche Maligne dell'Adulto (GIMEMA) proposes its multi-institutional effort as a working model. In total, 1138 newly diagnosed Binet stage A patients managed over the last 10 years outside the setting of clinical trials according to a {"}wait and see{"} policy form the basis of the present study aimed at investigating prognostic variables affecting disease progression, a surrogate endpoint for overall survival. A 3-stage risk system, simply obtained by summing the variables that proved significant in the multivariate analysis (i.e. short lymphocyte doubling time, advanced Rai substage, high peripheral blood lymphocytosis), is proposed. Clear-cut differences in the 10 year progression-free survival (PFS) were observed among patients scoring 0 (low risk), 1 (intermediate risk), 2 - 3 (high risk): 67.8, 41.0 and 24.8{\%}, respectively (P <0.0001). The results of the Medical Research Council (MRC) suggesting a better clinical outcome for females prompted us to verify such a gender-related difference within our prognostic categories. Because changes in PFS only reflected gender for patients scoring 0 (P = 0.04), the following prognostic subgroups are proposed: (1) females scoring 0; (2) males scoring 0; (3) patients scoring 1 - 3 whatever gender (10 year PFS: 76.2, 61.4 and 37.8{\%}; P <0.00001). Our long-term database provides an adequate patient sample to generate a generalized risk stratification model based on clinical data. The indolent clinical outcome of women with early CLL is also supported by the higher frequency of the immunoglobulin heavy-chain variable (IgVH) mutational status and lower proportion of 17p and 11q deletions found in such a patient subset in the MRC CLL4 trial.",
keywords = "Disease progression, Early CLL, Gender",
author = "Stefano Molica and Mauro, {Francesca R.} and Vincenzo Callea and Massimo Gentile and Diana Giannarelli and Manuela Lopez and Francesco Lauria and Bruno Rotoli and Marco Montanaro and Agostino Cortelezzi and Vincenzo Liso and Franco Mandelli and Robin Foa and Leoni, {[No Value]} and Montanari, {[No Value]} and Giustolisi, {[No Value]} and Stagno, {[No Value]} and Molica, {[No Value]} and D'Arco, {[No Value]} and Chiurazzi, {[No Value]} and Mariani, {[No Value]} and Iannitto, {[No Value]} and Mirto, {[No Value]} and Felici, {[No Value]} and Ascari, {[No Value]} and Invernizzi, {[No Value]} and Nobile, {[No Value]} and Leone, {[No Value]} and Laurenti, {[No Value]} and Longinotti, {[No Value]} and Dore, {[No Value]} and Lazzarino, {[No Value]} and Pagnucco, {[No Value]} and {Del Favero}, Favero and Liberati, {[No Value]} and Gallamini, {[No Value]} and Zanella, {[No Value]} and Barcellini, {[No Value]} and Maiolo, {[No Value]} and Petrini, {[No Value]} and Galimberti, {[No Value]} and Marotta, {[No Value]} and Niscola, {[No Value]} and Torelli, {[No Value]} and Morselli, {[No Value]} and Andriani, {[No Value]} and Zamboni, {[No Value]} and Miraglia, {[No Value]}",
year = "2005",
month = "4",
doi = "10.1080/10428190400029965",
language = "English",
volume = "46",
pages = "553--560",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "4",

}

TY - JOUR

T1 - A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia

AU - Molica, Stefano

AU - Mauro, Francesca R.

AU - Callea, Vincenzo

AU - Gentile, Massimo

AU - Giannarelli, Diana

AU - Lopez, Manuela

AU - Lauria, Francesco

AU - Rotoli, Bruno

AU - Montanaro, Marco

AU - Cortelezzi, Agostino

AU - Liso, Vincenzo

AU - Mandelli, Franco

AU - Foa, Robin

AU - Leoni, [No Value]

AU - Montanari, [No Value]

AU - Giustolisi, [No Value]

AU - Stagno, [No Value]

AU - Molica, [No Value]

AU - D'Arco, [No Value]

AU - Chiurazzi, [No Value]

AU - Mariani, [No Value]

AU - Iannitto, [No Value]

AU - Mirto, [No Value]

AU - Felici, [No Value]

AU - Ascari, [No Value]

AU - Invernizzi, [No Value]

AU - Nobile, [No Value]

AU - Leone, [No Value]

AU - Laurenti, [No Value]

AU - Longinotti, [No Value]

AU - Dore, [No Value]

AU - Lazzarino, [No Value]

AU - Pagnucco, [No Value]

AU - Del Favero, Favero

AU - Liberati, [No Value]

AU - Gallamini, [No Value]

AU - Zanella, [No Value]

AU - Barcellini, [No Value]

AU - Maiolo, [No Value]

AU - Petrini, [No Value]

AU - Galimberti, [No Value]

AU - Marotta, [No Value]

AU - Niscola, [No Value]

AU - Torelli, [No Value]

AU - Morselli, [No Value]

AU - Andriani, [No Value]

AU - Zamboni, [No Value]

AU - Miraglia, [No Value]

PY - 2005/4

Y1 - 2005/4

N2 - To facilitate the development of a prognostic model for early B-cell chronic lymphocytic leukemia (CLL), the Gruppo Italiano Malattie EMatologiche Maligne dell'Adulto (GIMEMA) proposes its multi-institutional effort as a working model. In total, 1138 newly diagnosed Binet stage A patients managed over the last 10 years outside the setting of clinical trials according to a "wait and see" policy form the basis of the present study aimed at investigating prognostic variables affecting disease progression, a surrogate endpoint for overall survival. A 3-stage risk system, simply obtained by summing the variables that proved significant in the multivariate analysis (i.e. short lymphocyte doubling time, advanced Rai substage, high peripheral blood lymphocytosis), is proposed. Clear-cut differences in the 10 year progression-free survival (PFS) were observed among patients scoring 0 (low risk), 1 (intermediate risk), 2 - 3 (high risk): 67.8, 41.0 and 24.8%, respectively (P <0.0001). The results of the Medical Research Council (MRC) suggesting a better clinical outcome for females prompted us to verify such a gender-related difference within our prognostic categories. Because changes in PFS only reflected gender for patients scoring 0 (P = 0.04), the following prognostic subgroups are proposed: (1) females scoring 0; (2) males scoring 0; (3) patients scoring 1 - 3 whatever gender (10 year PFS: 76.2, 61.4 and 37.8%; P <0.00001). Our long-term database provides an adequate patient sample to generate a generalized risk stratification model based on clinical data. The indolent clinical outcome of women with early CLL is also supported by the higher frequency of the immunoglobulin heavy-chain variable (IgVH) mutational status and lower proportion of 17p and 11q deletions found in such a patient subset in the MRC CLL4 trial.

AB - To facilitate the development of a prognostic model for early B-cell chronic lymphocytic leukemia (CLL), the Gruppo Italiano Malattie EMatologiche Maligne dell'Adulto (GIMEMA) proposes its multi-institutional effort as a working model. In total, 1138 newly diagnosed Binet stage A patients managed over the last 10 years outside the setting of clinical trials according to a "wait and see" policy form the basis of the present study aimed at investigating prognostic variables affecting disease progression, a surrogate endpoint for overall survival. A 3-stage risk system, simply obtained by summing the variables that proved significant in the multivariate analysis (i.e. short lymphocyte doubling time, advanced Rai substage, high peripheral blood lymphocytosis), is proposed. Clear-cut differences in the 10 year progression-free survival (PFS) were observed among patients scoring 0 (low risk), 1 (intermediate risk), 2 - 3 (high risk): 67.8, 41.0 and 24.8%, respectively (P <0.0001). The results of the Medical Research Council (MRC) suggesting a better clinical outcome for females prompted us to verify such a gender-related difference within our prognostic categories. Because changes in PFS only reflected gender for patients scoring 0 (P = 0.04), the following prognostic subgroups are proposed: (1) females scoring 0; (2) males scoring 0; (3) patients scoring 1 - 3 whatever gender (10 year PFS: 76.2, 61.4 and 37.8%; P <0.00001). Our long-term database provides an adequate patient sample to generate a generalized risk stratification model based on clinical data. The indolent clinical outcome of women with early CLL is also supported by the higher frequency of the immunoglobulin heavy-chain variable (IgVH) mutational status and lower proportion of 17p and 11q deletions found in such a patient subset in the MRC CLL4 trial.

KW - Disease progression

KW - Early CLL

KW - Gender

UR - http://www.scopus.com/inward/record.url?scp=20244381529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20244381529&partnerID=8YFLogxK

U2 - 10.1080/10428190400029965

DO - 10.1080/10428190400029965

M3 - Article

VL - 46

SP - 553

EP - 560

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 4

ER -